Original Research

Myo-Inositol Supplementation as an Adjunct to Antenatal Care: A Prospective Cohort Study on Its Impact on Preventing Foetal Growth Restriction in Pregnant Women in Rawalpindi, Pakistan

DOI https://doi.org/10.70302/jpsim.v7i4.2666
Received: 22 Oct 2026 Accepted: 20 Nov 2026 Published Online: 20 Nov 2026

Abstract

Objective:

To evaluate the efficacy of myo-inositol supplementation as an adjunct to standard antenatal care in preventing FGR among pregnant women.

Methodology:

This prospective cohort study was undertaken at Fauji Foundation Hospital, Rawalpindi. Participants were allocated to two cohorts: the exposed group received MI supplementation (2 g/day) alongside standard antenatal care, while the unexposed group received standard care alone. Females with at least one FGR risk factor were included. Outcome include FGR incidence, birth weight, gestational diabetes mellitus (GDM), pregnancy-induced hypertension (PIH), preterm birth, and neonatal outcomes.

Results:

The FGR incidence was significantly lower in the MI group (12.7%, 14/110) compared to the control group (25.5%, 28/110; RR=0.50, 95% CI: 0.28–0.89, p=0.018). Mean birth weight was higher in the MI group (3.1 kg vs. 2.7 kg, p=0.002). GDM incidence was reduced (9.1% vs. 20.0%, RR=0.45, p=0.022), as were PIH (10.9% vs. 21.8%, p=0.025) and preterm birth (8.2% vs. 16.4%, p=0.049). Neonatal intensive care unit (NICU) admissions were lower (7.3% vs. 14.5%, p=0.042). MI was well-tolerated, with 92% adherence.

Conclusion:

Myo-inositol supplementation (2 g/day) as an adjunct to antenatal care significantly reduces FGR incidence by 50% and improves maternal and neonatal outcomes.

Keywords:
Myo-inositol Foetal growth restriction Gestational diabetes Pregnancy-induced hypertension Antenatal care Pakistan

How to Cite This Article

Masoud A, Ibrar F, Kausar S, Salman N, Ayub N. Myo-Inositol Supplementation as an Adjunct to Antenatal Care: A Prospective Cohort Study on Its Impact on Preventing Foetal Growth Restriction in Pregnant Women in Rawalpindi, Pakistan. J Pak Soc Intern Med. 2026;7(4):332–336. doi:10.70302/jpsim.v7i4.2666

⭳ Download XML (JATS)

Conflict of Interest

The authors declare no conflict of interest.

Disclosed in accordance with ICMJE and COPE guidelines.

Funding

This research received no specific grant from any funding agency.

Funder information follows the Crossref Funder Registry standard.

Author Contributions

AM: Conception.
FI: Design of the work.
SK, NS, NA: Data acquisition, analysis, or interpretation.
SK, NS, NA: Draft the work.
AM, FI: Review critically for important intellectual content.
All authors approve the version to be published.
All authors agree to be accountable for all aspects of the work.

Contributions are recorded against the ICMJE criteria for authorship.

Data Availability

Data are available from the corresponding author on reasonable request.

Ethics Statement

This study was approved by Institutional Review Board of Advanced Educational Institute and Research Center. Approval number: ERC/554/P-034, dated October 24, 2024.

Conducted in accordance with the Declaration of Helsinki.

References

  1. Akhtar S, Zuberi BF, Awan S. Prevalence and risk factors of intrauterine growth restriction in a tertiary care hospital of Karachi. J Pak Med Assoc. 2020;70(5):845-50.
  2. Bernstein I, Gabbe SG, Reed KL. Intrauterine growth restriction. In: Obstetrics: Normal and Problem Pregnancies. Gabbe SG et al., eds. New York: Churchill Livingstone; 2002:869.
  3. National Institute of Population Studies (NIPS) [Pakistan], ICF. Pakistan Demographic and Health Survey 2017-18. Islamabad: NIPS and ICF; 2019.
  4. Brar HS, Rutherford SE. Classification of intrauterine growth retardation. Semin Perinatol. 1988;12(1):2-10.
  5. Guo F, Long Y, Zhou Z. Myoinositols prevent gestational diabetes mellitus and related complications: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2023;15(19):4224. doi:10.3390/nu15194224. doi:10.3390/nu15194224
  6. D'Anna R, Di Benedetto V, Rizzo P. Myo-inositol supplementation for prevention of gestational diabetes in obese pregnant women: a randomized controlled trial. Gynecol Endocrinol. 2015;31(5):375-9.
  7. Wang RT, Feng YQ, Wang MY, Wei YH, Huang YJ, Guo YJ, et al. Efficacy of inositol supplementation in the prevention and treatment of gestational diabetes mellitus: a meta-analysis. World J Diabetes. 2025;16(9):107871.
  8. Pandit G, Raut A, Gulhane S. Efficacy of myoinositol supplementation in reducing foetal growth restriction. Indian Obstet Gynaecol. 2025;15(1):14-17.
  9. Croze ML, Soulage CO. Potential role and therapeutic interests of myo-inositol in metabolic diseases. Biochimie. 2013;95(10):1811-27.
  10. Vitale K, Cesari E, Parrettini S. Myo-inositol plus α-lactalbumin supplementation, insulin resistance, and birth outcomes in pregnant women: a randomized controlled trial. Sci Rep. 2021;11(1):8832.
  11. Laganà AS, Vitagliano A, Noventa M, Ambrosini G, D’Anna R. Myo-inositol supplementation reduces the amount of gonadotropins and length of ovarian stimulation in women undergoing IVF: a systematic review and meta-analysis of randomized controlled trials. Arch Gynecol Obstet. 2018;298(4):675-684.
  12. Asimakopoulos G, Pergialiotis V, Antsaklis P, Theodora M, Loutradis D, Daskalakis G. Effect of dietary myo-inositol supplementation on the insulin resistance and the prevention of gestational diabetes mellitus: an open-label, randomized controlled trial. Arch Gynecol Obstet. 2024;310(4):1895-903.
  13. Dessì A, Fanos V. Myoinositol: a new marker of intrauterine growth restriction? J Obstet Gynaecol. 2013;33(8):776-80.
  14. Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci. 2003;7(6):151-9.
  15. D'Anna R, Scilipoti A, Giordano D. myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study. Diabetes Care. 2013;36(4):854-7.
  16. Soothill PW, Nicolaides KH, Campbell S. Prenatal asphyxia, hyperlacticaemia, hypoglycaemia, and erythroblastosis in growth retarded fetuses. Br Med J. 1987;294(6579):1051-1053.
  17. Cavalli P, Ronda E. Myoinositol: The Bridge (PONTI) to Reach a Healthy Pregnancy. Int J Endocrinol. 2017;2017:5846286.
  18. Motuhifonua SK, Lin L, Alsweiler J, Crawford TJ, Crowther CA. Antenatal dietary supplementation with myo-inositol for preventing gestational diabetes. Cochrane Database Syst Rev. 2023;2(2):CD011507.

Reference list indexed for Google Scholar and ResearchGate. DOI links resolve via doi.org.

CC BY CC BY 4.0 This article is published under the Creative Commons Attribution 4.0 International License. May be shared and adapted with attribution. Authors retain copyright. © 2026 The Author(s).